PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
This study is a prospective, open-label, phase II clinical study for patients with HR+/HER2- advanced breast cancer.
Breast Cancer Metastatic
DRUG: Fluzoparib|DRUG: Dalpiciclib|DRUG: Fulvestrant/AI
PFS, time to progressive disease (according to RECIST1.1), Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the end of study (approximately 5 years)
ORR, The proportion of participants whose best outcome is complete remission or partial remission (according to RECIST1.1), Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the end of study (approximately 5 years)|CBR, the percentage of subjects with CR+PR+SD and last more than 24 weeks in all of the participants., : Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the end of study (approximately 5 years)|OS, time to death due to any cause, Randomization to death from any cause, through the end of study (approximately 5 years)
Patients with SNF3 subtype of HR+/HER2- advanced breast cancer confirmed by the Department of Pathology and Key Laboratory of Breast Cancer of Fudan University Affiliated Cancer Hospital are planned to be enrolled. The main purpose is to evaluate efficacy of PARP inhibitor in SNF3 subtype of HR+/HER2- advanced breast cancer and prepare for subsequent randomized controlled phase III clinical studies with larger sample size.